Recent Updates
Recently added Catalysts

Jade Biosciences, Inc.

JBIOFDA catalysts, PDUFA dates & pipeline intelligence
$15.07
▲ +0.97 · +6.88%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full JBIO financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $8.3652W HIGH $28.00
Volume
595.38 K
Value Traded
8.83 M
Short % Float
20.57%
Days to Cover
10.9
+7.18%Week
+9.44%1 Month
-31.38%3 Month
-41.61%6 Month
-97.73%5 Year
-97.73%All Time

Cash Data

Unlock JBIO cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
958.41 M
EPS (TTM)
-2.97
P/E Ratio
-
Ent. Value
497.21 M
Total Shares
63.60 M
Float Shares
54.50 M
Insiders
14.30%
Institutions
105.70%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2 interim results
JADE101
Immunoglobulin A nephropathy (IgAN)
Phase 2BiologicsRenal/Genitourinary System
Unlock every JBIO catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

JBIO Catalyst Timeline

Dated clinical, regulatory and corporate events for Jade Biosciences, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Jade Biosciences, Inc.

118Total events
16Upcoming
21Tier-1 (high impact)
2024 to 2028Coverage

Upcoming catalysts 2

T1Interim Analysis
Subscribe to view catalyst details
JADE201
T1Interim Analysis
Subscribe to view catalyst details
JADE101

Event history 50

●Poster PresentationJADE101Presentation
JUNIPER Phase 2 Trial-in-Progress poster at ASN Kidney Week 2026 (INFO13-SA)
IgA nephropathysource ↗
●Poster PresentationJADE101Presentation
Model-based assessment of APRIL blockade informing JADE101 development poster at ASN Kidney Week 2026 (TH-PO0822)
IgA nephropathysource ↗
●Poster PresentationJADE301Presentation
JADE301 preclinical data e-poster presented at EADV 2026 (Poster #P1813)
dermatomyositissource ↗
▲Preclinical PoCJADE301Preclinical
Preclinical data characterizing JADE301 presented at EADV 2026
dermatomyositissource ↗
●R&D DayPresentation
Jade Biosciences conference call and webcast to discuss JADE301 profile
▲Interim AnalysisJADE101Trial
Positive interim Phase 1 data for JADE101 announced
IgA nephropathysource ↗
▲Oral PresentationJADE101Presentation
Phase 1 JADE101 data presented at 63rd ERA Congress
IgA nephropathysource ↗
▲Trial InitiationJADE101Trial
Dosing began in Phase 2 JUNIPER trial of JADE101
IgA nephropathysource ↗
●Poster PresentationJADE101Presentation
JUNIPER Trial-in-Progress update presented at ERA Congress
IgA nephropathysource ↗
▲Trial InitiationJADE201Trial
Dosing began in Phase 1 trial of JADE201 in rheumatoid arthritis
rheumatoid arthritissource ↗
Unlock the full JBIO catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How JBIO actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-09-30JADE301 Pre-clinical data readout Pre-clinical
Unlock 1 more JBIO historical catalyst
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 24%
Micro Cap
(rank 162 of 673)
Percentile Rank
Showing 2 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
JADE101 BiologicsNCT07541287IgA NephropathyPhase 3 RECRUITING 510Apr 1, 2029
JADE201 BiologicsNCT07533955Rhematoid ArthritisPhase 1 RECRUITING 36Oct 1, 2028
Unlock the JBIO pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every JBIO program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
JADE101 IgA nephropathyPhase 12026-08-10Mean IgA reductions reached approximately 70% from baseline after a single 700 mg dose.; Greater than 70% IgA reductions simulated at steady state with a single 350 mg subcutaneous maintenance injection every 12 weeks following one 700 mg induction dose.Read MoreJade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateRead More
Scroll for more · summaries link to the source press release
Unlock every JBIO trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock JBIO insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Eisner MarkDirectorGrant/Award 47,675 47,675 held$0.00 06/25/2026
Unlock the full JBIO insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Fairmount Funds Management LLC 6.7 % (45.7 %) 101.18 M 4.55 M
Unlock every fund holding JBIO
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in JBIO
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see JBIO ownership
Insider and institutional ownership, quarter by quarter.

JBIO Short Interest

Shares sold short, counted twice a month.

20.57%
Short % of Float
of tradable shares sold short
11.2M
Shares Sold Short
-7.5% vs prior count
10.9 Very high
Days to Cover
trading days of normal volume to buy every short share back
1.0M
Avg Daily Volume
the average used for days to cover
Unlock JBIO short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock JBIO option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live JBIO option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock JBIO options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How JBIO ranks across every disease it competes in

Competitive Position is a premium feature
See how JBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

JBIO News

JBIO
Nov 3, 2026
JBIOConferences/Events
▲ +6.9%today

Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences, a clinical-stage biotechnology firm, announced its participation in several upcoming conferences. These include the Guggenheim Healthcare Innovation Conference and the Stifel Healthcare Conference, among others. The management team will also hold one-on-one investor meetings during these events. Live webcasts of the discussions will be accessible on the company's website.

Read more →
JBIO
Oct 21, 2026
JBIOConferences/Events

Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026

Jade Biosciences will present advancements in its JADE101 program at ASN Kidney Week 2026. The EVERGREEN Phase 3 trial is now set to begin in Q4 2026, while interim data from the JUNIPER Phase 2 trial is anticipated in Q2 2027. The company aims to address IgA nephropathy with its novel monoclonal antibody.

Read more →
JBIO
Sep 30, 2026
JBIOPhases

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026

Jade Biosciences has announced promising preclinical data for JADE301, an anti-IFN-β monoclonal antibody aimed at treating dermatomyositis. The data, presented at the EADV Congress, indicates that JADE301 has a high affinity for its target and a significantly extended half-life, supporting its potential for infrequent dosing. A Phase 1 trial is expected to begin in late 2026.

Read more →
JBIO
Aug 10, 2026
JBIOPhases

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences reported positive interim Phase 1 results for its drug JADE101, indicating potential for effective treatment in IgA nephropathy. The company is advancing its clinical trials, with a Phase 2 trial underway and a Phase 3 trial expected to begin in 2027. Financially, Jade holds $461 million in cash, providing a solid runway into 2028 despite a net loss of $55.8 million in Q2 2026.

Read more →
JBIO
Jun 26, 2026
JBIOGeneral

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors

Jade Biosciences has appointed Dr. Mark Eisner to its Board of Directors, effective June 25, 2026. Dr. Eisner, with over 25 years of experience in clinical development and immunology, is expected to enhance the company's capabilities in advancing its antibody-based therapies for autoimmune diseases. His previous roles include leadership positions at Vir Biotechnology and Genentech.

Read more →
JBIO
Jun 5, 2026
JBIOGeneral

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Jade Biosciences has successfully closed a public offering of 11.5 million shares, raising $172.5 million. The offering included a full exercise of the underwriters' option to purchase additional shares. The company plans to use the proceeds to fund clinical trials and research activities. Jefferies, TD Cowen, and UBS Investment Bank managed the offering.

Read more →
JBIO
Jun 4, 2026
JBIOGeneral

Jade Biosciences Announces Pricing of Public Offering of Common Stock

Jade Biosciences has announced the pricing of a public offering of 10 million shares at $15.00 each, aiming to raise $150 million. The proceeds will fund clinical trials and research activities. The offering is expected to close on June 5, 2026, pending customary conditions. The company is focused on therapies for autoimmune diseases.

Read more →
JBIO
Jun 3, 2026
JBIOGeneral

Jade Biosciences Announces Proposed Underwritten Public Offering

Jade Biosciences, a clinical-stage biotechnology company, announced its intention to conduct an underwritten public offering of common stock and pre-funded warrants. The proceeds will support clinical trials and R&D efforts. The offering is subject to market conditions, and there is no guarantee of completion or specific terms. Jefferies, TD Cowen, and UBS are managing the offering.

Read more →
JBIO
Jun 1, 2026
JBIOPhases
▼ -11.6%on this newsshared move

JADE101 Phase 1 Interim Data

Jade Therapeutics presented interim data on its JADE101 Phase 1 study, highlighting that it has met objectives and demonstrated a favorable safety profile. The data suggests the potential for every-12-week subcutaneous dosing with significant IgA reduction. However, the company cautioned that interim results are not necessarily indicative of final outcomes and that various risks could impede future clinical trials and regulatory approvals.

Read more →
JBIO
Jun 1, 2026
JBIOPhases
▼ -11.6%on this newsshared move

Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy

Jade Biosciences announced positive interim results from its Phase 1 trial of JADE101, an investigational treatment for IgA nephropathy. The trial showed significant IgA reductions sustained at 12 weeks, with a favorable safety profile. The company plans to advance to Phase 2 and initiate a Phase 3 trial in 2027, aiming for best-in-class status in treatment.

Read more →
JBIO
May 29, 2026
JBIOConferences/Events

Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy

Jade Biosciences announced a conference call on June 1, 2026, to discuss interim results from its Phase 1 study of JADE101, a monoclonal antibody for IgA nephropathy. The results are expected to inform dosing strategies and clinical profiles. JADE101 aims to be a best-in-class treatment for this autoimmune kidney disease.

Read more →
JBIO
May 26, 2026
JBIOPhases

Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy

Jade Biosciences has announced the dosing of the first participant in its Phase 2 JUNIPER clinical trial for JADE101, aimed at treating immunoglobulin A nephropathy (IgAN). The trial will assess safety, tolerability, and efficacy in approximately 30 participants. Interim data is anticipated in 2027, showcasing the potential of JADE101 as a treatment option.

Read more →
JBIO
May 26, 2026
JBIOPhases

Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody

Jade Biosciences has initiated a Phase 1 clinical trial for JADE201, a novel monoclonal antibody targeting BAFF-R to treat autoimmune diseases. The first participant has been dosed, with interim data expected in 2027. JADE201 aims to enhance B cell depletion while allowing for less frequent dosing, addressing limitations of existing therapies.

Read more →
JBIO
May 7, 2026
JBIOGeneral

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences reported its Q1 2026 financial results, highlighting upcoming clinical trials for its lead candidate, JADE101, and the initiation of JADE201. The company has a robust cash position of $311 million, expected to sustain operations until mid-2028. However, it also reported a net loss of $40.4 million due to increased R&D expenses.

Read more →
JBIO
Apr 23, 2026
JBIOGeneral

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jade Biosciences has appointed Dr. Edward R. Conner as Chief Medical Officer, granting him 500,000 stock options under the Inducement Plan. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to the company. Jade focuses on innovative therapies for autoimmune diseases, including its lead candidate, JADE101.

Read more →
JBIO
Apr 22, 2026
JBIOGeneral
▲ +10.3%on this newsshared move

Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer

Jade Biosciences has appointed Dr. Edward R. Conner as Chief Medical Officer, effective immediately. Dr. Conner brings extensive experience in clinical development and regulatory strategy, which will aid in advancing the company's pipeline of therapies for autoimmune diseases. The company is preparing for key milestones, including Phase 1 data for JADE101 and a Phase 2 trial in IgA nephropathy.

Read more →
JBIO
Mar 6, 2026
JBIOPhases

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Jade Biosciences, Inc. has reported its financial results for Q4 and FY 2025, highlighting strong momentum in its clinical development programs. The company has initiated its JADE101 Phase 1 study and is advancing its pipeline, including plans for the JADE201 trial to start in 2026. The focus remains on achieving key milestones, with cash reserves sufficient to support operations until 2028. However, the update also reflects financial losses and acknowledges potential risks associated with upcoming trials.

Read more →
JBIO
Jan 5, 2026
JBIOGeneral
▼ -7.3%on this news

Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference

Jade Biosciences expects cash and investments of approximately $336 million as of December 31, 2025. This balance provides funding runway into the first half of 2028. The company plans to initiate a Phase 2 trial for JADE101 in IgA nephropathy by mid-2026. Interim data from the ongoing Phase 1 study is expected in the first half of 2026.

Read more →

About Jade Biosciences, Inc.

Waltham, MA 55 employees jadebiosciences.com
Headquarters221 CRESCENT ST., WALTHAM, MA, 02453
BIOPHARMAWATCH ELITE PLUS
Trade the next JBIO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime